PHXM

PHAXIAM Therapeutics S.A.

NASDAQ: PHXM · HEALTHCARE · BIOTECHNOLOGY

$3.10

+0.00% today

Updated 2026-06-05

Market cap

$28.90M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-39.05

Dividend yield

—

52W range

$0 – $0

Volume

—

Market cap

$28.90M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-39.05

Dividend yield

—

52W range

$0 – $0

Volume

—

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

3.7

Growth

4.8

Quality

2.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →204 stocks currently score above 75

Price targets

Analyst target

—

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.43x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Thin margins at -191.00%

- Negative free cash flow $-12.71M

- Revenue declining -66.40% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2020	2021	2022	2023	TTM
Revenue	$0.00	$0.00	$0.00	—	$5.97M
Net income	$-73.30M	$-53.80M	$-227000.00	$-23.49M	$-11.29M
EPS	—	—	—	—	$-39.05
Free cash flow	$-52.86M	$-57.07M	$-31.85M	$-24.58M	$-12.71M
Profit margin	—	—	—	—	-191.00%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
PHXM	$28.90M	11	3.7	2.0	5.0	4.8	—	Avoid
LLY	$1.08T	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$613.02B	57	4.7	9.0	3.3	6.0	-87.08%	Buy
ABBV	$447.62B	63	4.0	8.0	4.7	5.0	-73.27%	Buy
UNH	$388.59B	54	5.3	5.5	4.0	5.5	-33.19%	Buy
NVS	$296.54B	49	3.3	9.0	3.3	4.5	-69.70%	Hold

Smart narrative

PHAXIAM Therapeutics S.A. trades at $3.10. Our Smart Value Score of 11/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. TTM revenue stands at $5.97M. with profit margins at -191.00%.

Frequently asked questions

What is PHAXIAM Therapeutics S.A.'s stock price?

PHAXIAM Therapeutics S.A. (PHXM) trades at $3.10.

Is PHAXIAM Therapeutics S.A. overvalued?

PHAXIAM Therapeutics S.A. carries a Smart Value Score of 11/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is PHAXIAM Therapeutics S.A.'s revenue?

PHAXIAM Therapeutics S.A.'s trailing twelve-month revenue is $5.97M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-63.18%

Beta1.96

50D MA$4.90

200D MA$7.21

Shares out0.01B

Float0.00B

Short ratio—

Avg volume—

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

PHXM vs LLY →PHXM vs JNJ →PHXM vs ABBV →Stock screener →